FI943355A - Menetelmä tietyn syövän esiintymismahdollisuuden arvioimiseksi potilaassa - Google Patents

Menetelmä tietyn syövän esiintymismahdollisuuden arvioimiseksi potilaassa Download PDF

Info

Publication number
FI943355A
FI943355A FI943355A FI943355A FI943355A FI 943355 A FI943355 A FI 943355A FI 943355 A FI943355 A FI 943355A FI 943355 A FI943355 A FI 943355A FI 943355 A FI943355 A FI 943355A
Authority
FI
Finland
Prior art keywords
patient
carcinoma
estimating
biopsy
assessing
Prior art date
Application number
FI943355A
Other languages
English (en)
Swedish (sv)
Other versions
FI943355A0 (fi
Inventor
Michael K Brawer
Original Assignee
Michael K Brawer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael K Brawer filed Critical Michael K Brawer
Publication of FI943355A0 publication Critical patent/FI943355A0/fi
Publication of FI943355A publication Critical patent/FI943355A/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
FI943355A 1992-01-15 1994-07-14 Menetelmä tietyn syövän esiintymismahdollisuuden arvioimiseksi potilaassa FI943355A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82112092A 1992-01-15 1992-01-15
PCT/US1993/000449 WO1993014407A1 (en) 1992-01-15 1993-01-15 A method for estimating the biologic potential of a selected carcinoma in a patient

Publications (2)

Publication Number Publication Date
FI943355A0 FI943355A0 (fi) 1994-07-14
FI943355A true FI943355A (fi) 1994-09-14

Family

ID=25232578

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943355A FI943355A (fi) 1992-01-15 1994-07-14 Menetelmä tietyn syövän esiintymismahdollisuuden arvioimiseksi potilaassa

Country Status (11)

Country Link
US (2) US5688694A (fi)
EP (1) EP0643839B1 (fi)
JP (1) JPH07503069A (fi)
AT (1) ATE145728T1 (fi)
AU (1) AU673153B2 (fi)
CA (1) CA2128031A1 (fi)
DE (1) DE69306250T2 (fi)
ES (1) ES2095038T3 (fi)
FI (1) FI943355A (fi)
NO (1) NO942653L (fi)
WO (1) WO1993014407A1 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053736A1 (en) * 1999-03-05 2000-09-14 Mitsubishi Rayon Co., Ltd. Carriers having biological substance
US6730313B2 (en) 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
AU2002217821B2 (en) 2000-11-06 2007-12-13 Board Of Regents, The University Of Texas System Laser scanning cytometry mediated analysis of therapeutic efficacy in tumors
US6993175B2 (en) * 2001-09-07 2006-01-31 Quest Diagnostics Investments Incorporated Methods for measuring microvascular density in tumors
US7229423B2 (en) * 2003-02-05 2007-06-12 Timi 3 System, Inc Systems and methods for applying audible acoustic energy to increase tissue perfusion and/or vasodilation
US20070100335A1 (en) * 2005-10-28 2007-05-03 Apple Medical Corporation Instrument for electrosurgical excision procedure for the uterine cervix
US8321010B2 (en) * 2009-09-04 2012-11-27 Konstantin Georgievich Korotkov Method for determining the condition of a biological object and device for making same
FR2964744B1 (fr) 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0553273A4 (en) * 1990-10-16 1998-04-22 Biomed Frontiers Inc Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging

Also Published As

Publication number Publication date
CA2128031A1 (en) 1993-07-22
US5688694A (en) 1997-11-18
EP0643839B1 (en) 1996-11-27
EP0643839A1 (en) 1995-03-22
NO942653L (no) 1994-09-12
US5616469A (en) 1997-04-01
FI943355A0 (fi) 1994-07-14
ATE145728T1 (de) 1996-12-15
AU673153B2 (en) 1996-10-31
JPH07503069A (ja) 1995-03-30
WO1993014407A1 (en) 1993-07-22
ES2095038T3 (es) 1997-02-01
DE69306250D1 (de) 1997-01-09
AU3478293A (en) 1993-08-03
DE69306250T2 (de) 1997-03-20
NO942653D0 (no) 1994-07-14

Similar Documents

Publication Publication Date Title
Paulson et al. Predictors of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study
Aiko et al. The new Japanese classification of gastric carcinoma: points to be revised
El‐Bolkainy et al. The impact of schistosomiasis on the pathology of bladder carcinoma
Koren et al. Lymph node-revealing solution: simple new method for detecting minute lymph nodes in colon carcinoma
Fukui et al. In vivo staining test with methylene blue for bladder cancer
Scaletscky et al. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen
DE69907156D1 (de) Krebsbehandlung
CY1106073T1 (el) Φασματογραφια μαγνητικου συντονισμου βιοψιας μαστου για τον προσδιορισμο της παθολογιας, της αγγειωσεως και της εμπλοκης οζιδιων
Díaz-Cascajo et al. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases
FI943355A (fi) Menetelmä tietyn syövän esiintymismahdollisuuden arvioimiseksi potilaassa
Shimada et al. Appraisal of surgical resection of gallbladder cancer with special reference to lymph node dissection
Ding et al. Depth of tumor invasion independently predicts lymph node metastasis in T2 rectal cancer
DE60108245D1 (de) Diagnostisches in vitro-verfahren für prostatakrebs sowie hierfür geeignetes testsystem
Schoonees et al. The diagnostic value of urinary cytology in patients with bladder carcinoma
Reintgen Melanoma nodal metastases: biologic significance and therapeutic considerations
DE60119731D1 (de) Immunologisches test und satz zur diagnose von prostatadenokarzinom
CA2100464A1 (en) Prescreening of prostate cancer by serum prostatic specific antigen
Winter et al. Preoperative prostate-specific antigen in predicting pathologic stage and grade after radical prostatectomy
Yamamoto et al. Raised prostate-specific antigen in adenocarcinoma of the colon
Reddy et al. Efficacy of FNAC in early diagnosis of prostatic carcinoma
Bartkus et al. Correspondence re: Carl S. Killian et al. Prognostic Importance of Prostate-specific Antigen for Monitoring Patients with Stage B2to D1Prostate Cancer. Cancer Res., 45: 886-891, 1985
de Voogt et al. Efficacy of urinary cytology in the detection of tumors of the urinary tract
Lowe Incidental prostate cancer: predictors of progression
Balbi et al. Method for the Determination of Nonmetallic Inclusions
Bowden et al. Increased incidence of prostate cancer in black patients/In reply

Legal Events

Date Code Title Description
FD Application lapsed